Search

Search Results
Results 151 - 160 of 265 for Myasthenia gravis
  • News - 30 Jan 2014
    Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion"...
  • News - 25 Jul 2012
    Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2012.
  • Drug - 19 Mar 2025
    Consumer Medicine Information (CMI) about DBL Dexamethasone Sodium Phosphate (Dexamethasone Phosphate) intended for persons living in Australia.
  • White Paper - 18 Feb 2025
    Explore the latest advancements and innovative technologies in ADC therapeutics, driving new possibilities for targeted drug delivery.
  • Drug - 24 Jan 2025
    Consumer Medicine Information (CMI) about Tobramycin Viatris (tobramycin) intended for persons living in Australia.
  • Drug - 26 Nov 2024
    Consumer Medicine Information (CMI) about Tobramycin Injection (tobramycin sulfate) intended for persons living in Australia.
  • Drug - 26 Nov 2024
    Consumer Medicine Information (CMI) about DBL Tobramycin Injection (tobramycin) intended for persons living in Australia.
  • Drug - 26 Nov 2024
    Consumer Medicine Information (CMI) about Tobramycin PF (tobramycin) intended for persons living in Australia.
  • Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about DBL Amikacin Injection (amikacin) intended for persons living in Australia.
  • Health - 13 Jul 2023
    Autoimmune conditions are multifactorial in their cause, with a mixture of genetic and environmental factors often playing a role.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.